Prior authorization for surgical interventions

Prior authorization is implied for implantable penile prostheses and penile re-vascularization because specific medical necessity criteria and documentation must be met before these surgical interventions are covered.

Prior authorization for prosthesis and surgical procedures

Certain penile prosthesis procedures and related prosthesis HCPCS codes are covered only when the policy's selection criteria are met; prior authorization may be required when billing CPT 54400–54417 or HCPCS C1813/C2622.

• Document that all medical criteria for implantation are satisfied (see policy selection criteria).

Prior authorization for surgical/device therapies

Surgical interventions and device implants (for example inflatable penile prosthesis or penile revascularization) typically require documentation of prior treatment attempts and indications consistent with guideline recommendations when requesting authorization.

• Include evidence of nonsurgical therapy failure or contraindication.
• Provide relevant guideline-based indications and counseling documentation.

Endovascular therapy — prior authorization considerations

Endovascular therapies for vasculogenic ED have limited, heterogeneous evidence; prior authorization should require documentation of a focal vascular lesion, prior conservative therapy failure, and discussion of limited long-term data.

• Document diagnostic imaging confirming focal arterial lesion or venous pathology.
• Provide record of prior medical management and counseling regarding limited durability.

Prior authorization for LI-ESWT

Prior authorization may be required for low-intensity extracorporeal shock wave therapy (LI-ESWT); when requested include the indication (e.g., vasculogenic ED, post-prostatectomy, diabetic ED), prior treatments tried, and objective outcome measures (IIEF, EHS) documented before and after therapy.

• Specify LI-ESWT protocol used and prior response to PDE5 inhibitors or other therapies.

PTT (RestoreX) authorization note

RestoreX is FDA-cleared and trial evidence describes typical home use (30–90 minutes/day), but the policy text does not define payer prior authorization requirements for this device; include device usage instruction and documented patient use if submitting for review.

• Document patient instruction and recorded daily use (minutes/day) and treatment duration in the medical record.

Prior authorization for stem cell or experimental biologic treatments

Prior authorization requests for stem cell therapy or other novel biologic injections should include clinical trial phase, safety data, validated outcome measures (IIEF/EHS), and supporting human evidence because current data are limited.

• Provide trial phase, sample size, follow-up duration, and safety outcomes.
• Document prior conventional therapy failure and inclusion criteria if part of a trial.

Follow plan-specific prior authorization

Follow the member's plan-specific prior authorization rules and program provisions; Clinical Policy Bulletins do not replace plan requirements and prior authorization may be required per plan rules.

• Verify member benefits and obtain any plan-required authorizations before scheduling procedures.

Step requirement before implantable devices

Penile prosthesis implantation is covered only after nonsurgical methods have proven ineffective or are contraindicated; failure to document prior therapy attempts may lead to noncoverage.

• Document trials of PDE5 inhibitors, vacuum devices, injections, or contraindications to these therapies.

First-line PDE-5 inhibitor therapy

Guideline-supported first-line therapy for ED is initiation of an oral PDE-5 inhibitor when not contraindicated; document use and response to PDE-5 inhibitors when relevant to authorization of advanced therapies.

• Record which PDE-5 inhibitor was used, dose, duration, and clinical response.

Step: start with PDE-5 inhibitors

When escalating therapy, start with a PDE-5 inhibitor in men without contraindications; authorization for invasive or device therapies should reflect documented trial and response to PDE-5 inhibitors.

• Include documentation of contraindications if PDE-5 inhibitors were not used.

Step considerations around bariatric surgery

When bariatric surgery is reported as a management option for ED, ensure prior optimization of medical management of ED and document obesity-related comorbidities and prior ED therapy attempts.

• Provide records of medical optimization and objective ED assessments pre- and post-intervention when available.

Adjunct use after PDE5i

For post-prostatectomy ED, LI-ESWT is often studied as an adjunct to PDE-5 inhibitors; consider documenting a trial of PDE5i and response status prior to authorization of LI-ESWT.

• Document timing of LI-ESWT relative to surgery and prior PDE5i therapy details.

No explicit step therapy sequences given

The policy excerpt provides no explicit step therapy sequences for devices or biologics; when seeking authorization, include documented prior treatments and clinical rationale even though no formal sequence is defined here.

Surgical approach guided by SUI severity

For synchronous surgical management of ED with stress urinary incontinence, surgical severity (e.g., severe SUI >4 pads/day) should guide choice of combined procedures; document SUI severity and rationale for combined approach.

• Record pad counts/day, urodynamic findings if available, and surgical plan justification.

Required diagnostic documentation

Providers must document a comprehensive history and physical, specified laboratory testing (including serum testosterone, prolactin, and thyroid studies when indicated), and appropriate diagnostic studies (e.g., duplexscan with intracorporeal papaverine) to support medical necessity.

• Include biothesiometry as part of the exam when performed.
• Provide results of duplex Doppler, cavernosometry/cavernosography when relevant.

Document selection criteria for covered codes

When billing CPT and HCPCS codes listed as 'covered if selection criteria are met' (for example CPT 54400–54417 or HCPCS C1813/C2622), document the medical necessity and the specific selection criteria used to justify coverage.

• Attach the policy selection criteria text or cite the clinical findings that meet each required element.

Testing and counseling documentation

Document morning serum total testosterone levels for men diagnosed with ED when indicated, and counsel patients about FDA‑approved PDE5 inhibitors and other options per AUA guidance; include counseling notes in the record.

• Record testosterone level values, date/time (morning sample), and any subsequent endocrine evaluation.

Documentation for investigational biologic therapy

For investigational biologic treatments (e.g., adipose-derived regenerative cells), document trial phase, inclusion/exclusion criteria, prior conventional therapy failure, and safety monitoring results when submitting for review.

• Include study identifiers (e.g., ClinicalTrials.gov number) if treatment is part of a clinical trial.

Documentation for investigational therapies

For investigational therapies such as fractional CO2 laser for Peyronie's disease, document the device used, treatment protocol (number and timing of sessions), concomitant topical/adjunct treatments, baseline and follow-up curvature measurements, validated questionnaires (IIEF, PDQ), and adverse events.

• Provide objective curvature measurements and dates of each treatment session.

PTT (RestoreX) usage documentation

Manufacturer and trial guidance report typical RestoreX use of about 30–90 minutes/day (commonly two 30‑minute sessions) with minimum 12 weeks and up to 24 weeks in some studies; document patient instruction and device usage time in records.

• Record daily minutes of device use and total weeks of therapy in the chart.

Required evidence details for experimental therapies

When submitting experimental therapies for review, include trial phase, sample size, follow-up duration, safety outcomes, and objective erectile function measures (e.g., IIEF, EHS) because the cited literature emphasizes limited cohorts and heterogeneous endpoints.

• Provide published study references and any available comparative data.

Documentation and plan provisions

Clinical Policy Bulletins are partial descriptions of plan benefits and not contracts; participating providers remain responsible for following plan-specific program provisions and disclosures when seeking authorization or billing.

• Confirm member eligibility and any plan-specific prior authorization or coverage limitations before treatment.

Penile prosthesis prerequisites (denial risk)

Failure to document that nonsurgical methods were ineffective or contraindicated, or failure to provide required lab documentation (normal prolactin, thyroid, and testosterone when indicated) may lead to denial of coverage for penile prosthesis implantation.

• Ensure labs and prior therapy attempts are in the medical record prior to submission for authorization.

Billing non-covered codes may be denied

Use of CPT/HCPCS codes listed as 'not covered for indications listed in the CPB' (for example 0038U, 0101T, 0232T, 11900–11901, 37790, or HCPCS E0201) may trigger claim denial when billed for the policy's stated indications.

• Avoid billing these codes for indications listed in the CPB unless plan exceptions or prior approvals are documented.

Investigational therapy denial risk

Therapies described as investigational or experimental such as platelet-rich plasma, intracavernosal stem cell injections, or some ESWT applications may be denied if billed as medically necessary without robust supporting evidence.

• If provided in research context, include trial documentation; otherwise expect coverage denial risk.

Risk for denial when using treatments lacking Level 1/2 support

Use of treatments with mixed or negative Level 1/2 evidence (e.g., iontophoresis/transdermal verapamil, certain oral therapies, ESWT for Peyronie's, intralesional verapamil/nicardipine) may be unsupported and could risk denial if billed as proven treatments.

• Document trial results and rationale when considering these therapies; preferentially enroll patients in trials.

Radial wave therapy unsupported — denial risk

Radial pressure wave therapy has no quality human evidence demonstrating benefit for ED; claims for this treatment may be denied or considered experimental based on lack of supporting data.

• Do not bill radial wave therapy for ED as standard care for indications listed in the CPB.

AUA states penile traction is promising

The AUA states penile traction is promising but evidence is insufficient for a formal recommendation; until larger rigorous trials are available, use may be considered unproven and could be subject to investigational coverage decisions.

• Document clinical rationale and device usage if seeking coverage consideration.

Investigational therapies may be denied

Treatments described as investigational or lacking robust human evidence (for example stem cell therapy for ED) may trigger coverage denial or require further evidence before authorization.

• Submit comprehensive human trial data, safety outcomes, and objective measures when requesting review.

Policy administrative note

Clinical Policy Bulletins do not constitute coverage guarantees; providers must follow plan-specific provisions and authorizations to avoid denials related to nonconformance with plan rules.

• Confirm benefit limitations and obtain required prior authorizations per the member's plan.